Lantheus Holdings, Inc. — Drug Manufacturers - Specialty & Generic. Scored on the same transparent 7-signal model behind the daily rankings.
★
LNTH
Lantheus Holdings, Inc. · Drug Manufacturers - Specialty & Generic
FCF$362mC
Rev+0.6%C
D/E0.52B
P/E24.5xB
PEG49.60D
52.6Score
$104.32$6.8B
1Y Target$110.33Analyst consensus · 12 analysts
5Y Target$161.54Compound horizon
10Y Target$239.63Long-dated conviction
FCF$362mTTMC
FCF $362m — modest; watch for margin expansion
Rev+0.6%TTM YoYC
Revenue +0.6% — flat, mature phase or headwinds present
D/E0.52B
D/E 0.52 — near the Healthcare debt median (≈60th pctile)
P/E24.5xB
P/E 24.5 — near the Healthcare median (≈60th pctile)
PEG49.60proxyD
PEG 49.60 — very expensive; pricing in best-case scenarios · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 52.6
Quality0.83
Growth0.66
Value0.27
Why this score
Buying back stock
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week high
7% off the 12-month high
vs DCF fair value9% belowest. fair value ~$114
What the price assumes: free cash flow compounding at ~9% a year for the next decade — vs the ~18% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability40% · B+gross profit ÷ total assets (Novy-Marx)
ROIC12.9% · B+return on invested capital — not score-weighted
Why now
Drug Manufacturers - Specialty & Generic · market cap $6.8b. 7% off the 52-week high of $111.86. 12 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $110.33 (implying +6% upside).
Moat
Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 130% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $110.33 (12-analyst consensus) — fundamentals + valuation re-rating. 5 yr $161.54 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $239.63 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · LNTH
Trend
-10.7 over 20 daily scores
From 63.3 (Jun 22) → 52.6 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · LNTH
$
%
%
Shares to buy
19
Position size
$1,982
4.0% of portfolio
Stop price
$78.24
25% below $104.32
$ at risk if stopped
$495.52
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Lantheus Holdings, Inc. (LNTH): score, valuation & FAQ
Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers - Specialty & Generic company that scores 52.6 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
The model flags PEG (D) as weaker areas. On valuation, LNTH sits about 9% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 9% annual free-cash-flow growth over the next decade.
Is LNTH a good stock to buy?
Bull Rankings scores LNTH 52.6 out of 100 on its quality-growth model, which is a middling reading. A score is a quantitative screen of Lantheus Holdings, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does LNTH score 52.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). LNTH grades middle-of-pack across the strip, and is held back by PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is LNTH overvalued or undervalued?
Based on $104.32, LNTH sits about 9% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 9% annual free-cash-flow growth over the next decade. It trades at a 24.5x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in LNTH?
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.